Announcements
Search
-
Research Update
December 5, 2019
Alzheimer’s Drug Discovery Foundation Reacts to Biogen’s New Data on Aducanumab
Dr. Howard Fillit, Founding Executive Director and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation (ADDF) shares his perspectives on the data presented today at the 12th Clinical Trials in Alzheimer’s Disease (CTAD) meeting in San Diego regarding the safety and efficacy of aducanumab as a potential new treatment for Alzheimer’s disease, particularly for people living with the early stages of the condition.
-
New Grants
December 4, 2019
Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator Announces Second Round of Awards
$50 million global research initiative, funded by Leonard A. Lauder, Bill Gates, Jeff and MacKenzie Bezos, among other leading philanthropists, targets resources to speed up development of blood, digital and other biomarkers for early detection of Alzheimer's disease and related dementias.
-
New Grants
November 22, 2019
Major Research Funding for Blood Test to Accelerate Clinical Trials for New Frontotemporal Degeneration (FTD) Therapies
The Bluefield Project to Cure FTD Receives $1.2 Million Award from the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator
-
Events
November 4, 2019
The Alzheimer's Drug Discovery Foundation Celebrates Tenth Anniversary of Annual Fall Symposium & Luncheon
CEO Pamela J. Newman of PJN Strategies Honored for Support of Alzheimer’s Research
-
Research Update
October 22, 2019
Alzheimer’s Drug Discovery Foundation Statement on Biogen Announcement to Plan FDA Filing of Aducanumab for Alzheimer’s Disease
The Alzheimer’s Drug Discovery Foundation is encouraged by today’s announcement from Biogen of its plans to seek regulatory approval for aducanumab as a potential new treatment for Alzheimer’s disease, particularly for people living with the early stages of Alzheimer’s.
-
Research Update
October 17, 2019
Alzheimer’s Drug Discovery Foundation Partners with Shionogi and Janssen Pharmaceuticals for its Diagnostics Accelerator Initiative
The Alzheimer’s Drug Discovery Foundation (ADDF) announced a partnership with Shionogi & Co., Ltd. and Janssen Pharmaceuticals, Inc. as part of its Diagnostics Accelerator, an initiative that aims to fast-track the development of novel biomarkers for the early detection of Alzheimer's disease and related dementias.
-
New Grants
October 15, 2019
$3.2 Million in New Funding Focused on Biomarkers and Moving Toward New Therapies
These recent investments reflect the ADDF's commitment to advancing tools for early detection, with an emphasis on exploring the different pathologies associated with aging.
-
Research Update
September 23, 2019
20th International Conference on Alzheimer’s Drug Discovery Showcases Diversity of Approaches - Reflects Two Decades of Scientific Advances
-
Events
September 20, 2019
Dr. Jeffrey Cummings Wins Alzheimer's Drug Discovery Foundation's (ADDF) Prestigious Melvin R. Goodes Prize
ADDF recognizes Dr. Cummings' significant contributions toward advancing clinical research for Alzheimer's disease
-
Research Update
July 15, 2019
ADDF Clinical Trials Report Shows Notable Shift from Amyloid Approach
The Alzheimer's Drug Discovery Foundation (ADDF) released a new clinical trial analysis report that shows researchers are now developing drugs for various targets associated with aging biology – moving beyond traditional amyloid and tau approaches.
-
Research Update
June 11, 2019
New Report Discourages Use of Dietary Supplements for Brain Health
The ADDF's Dr. Howard Fillit served as an expert contributor to The Global Council on Brain Health's report on brain health supplements.
-
Events
May 31, 2019
Thirteenth Connoisseur's Dinner Recognizes Core Funders of Its Diagnostics Accelerator
The ADDF celebrated the one-year anniversary of the Diagnostics Accelerator initiative and its core funders at the ADDF's annual gala.
-
Initiatives
May 30, 2019
Alzheimer’s Drug Discovery Foundation Announces the First Award Recipients of its Diagnostics Accelerator Program
The first four awards from the first request for proposals total up to approximately $3.5 million.
-
New Grants
May 10, 2019
$7.1 Million in New Funding Illustrates the ADDF’s Strong Support of a Diverse Pipeline
The ADDF announces $7.1 million in new investments, which reflect our strategy to advance drug discovery and clinical trials, including the development of biomarkers and prevention methods.
-
Events
May 2, 2019
T.J. Oshie and Dr. Michela Gallagher Honored at Ninth Annual Great Ladies Luncheon
Hosted by Lindsay Czarniak, the Ninth Annual Great Ladies Luncheon & Fashion Show honored T.J. Oshie of the Washington Capitals and Dr. Michela Gallagher, founder and CEO of AgeneBio.
-
Board & Staff
April 15, 2019
Second Memories Matter Benefit Raises Over $1 Million for Alzheimer’s Drug Research
On April 9, the ADDF celebrated its second annual Memories Matter benefit event, which raised over $1 million.
-
Initiatives
April 2, 2019
Alzheimer’s Drug Discovery Foundation Announces New Research Initiative to Advance Digital Tools for Detection of Alzheimer’s and Related Dementias
The ADDF's Diagnostics Accelerator is seeking to fund the development of digital tools to capture quantifiable biomarkers.
-
Research Update
March 21, 2019
Alzheimer’s Drug Discovery Foundation Statement on Biogen and Eisai Announcement to Discontinue Trials of Aducanumab in Alzheimer's Disease
Pharmaceuticals company Biogen and its partner Eisai announced that they will cease clinical trials for aducanumab after it was indicated the trials were unlikely to succeed.
-
Events
March 4, 2019
Marcia Gay Harden Honored at Hope on the Horizon Women’s Luncheon in Palm Beach
The Second Annual Hope on the Horizon Palm Beach Luncheon honoring Marcia Gay Harden raised over $350,000 for the ADDF.
-
New Grants
February 19, 2019
Alzheimer’s Drug Discovery Foundation and Harrington Discovery Institute Invite Applications for 2019 ADDF-Harrington Scholar Award
Harrington Discovery Institute at University Hospitals and the Alzheimer's Drug Discovery Foundation announce a joint request for proposals for the 2019 ADDF-Harrington Scholar Award.
-
New Grants
January 11, 2019
New Funding Focuses on Prevention
The Alzheimer's Drug Discovery Foundation awarded new funding to studies that focus on prevention.
-
Research Update
January 9, 2019
New Generation of Therapeutics Based on Understanding of Aging Biology Show Promise for Alzheimer’s
A review by the ADDF published in Neurology® explores novel approaches beyond the common amyloid that could slow or prevent Alzheimer's.
-
Initiatives
January 3, 2019
The Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator Initiative Expands Its Focus on Frontotemporal Degeneration
The ADDF's Diagnostics Accelerator is matching a $2.5 million research investment from The Association for Frontotemporal Degeneration to invest in biomarkers for frontotemporal dementia.
-
Events
November 5, 2018
CEO David R. Weinreb of The Howard Hughes Corporation Honored for Support of Alzheimer’s Research
The Alzheimer's Drug Discovery Foundation's Ninth Annual Fall Symposium & Luncheon raised a record-breaking total of over $1.6 million.
-
Board & Staff
October 23, 2018
Justice Sandra Day O’Connor’s Announcement of Dementia Diagnosis
The Alzheimer's Drug Discovery Foundation is saddened to hear the news that former Supreme Court Justice Sandra Day O'Connor has been diagnosed with the beginning stages of dementia.
-
Research Update
September 21, 2018
19th International Conference on Alzheimer's Drug Discovery Highlights Multiple Approaches to Prevent and Treat Alzheimer's Disease
The conference, organized by the Alzheimer's Drug Discovery Foundation, focused on gene therapy and alternative modalities for neurodegenerative diseases, progress in developing novel drugs, as well as the need for new biomarkers.
-
Events
September 17, 2018
Dr. Michela Gallagher Wins Alzheimer's Drug Discovery Foundation's Prestigious Melvin R. Goodes Prize
Michele Gallagher, PhD, is the recipient of the fourth Melvin R. Goodes Prize, which includes a $150,000 award to support the therapeutic development of AGB-101.
-
New Grants
September 13, 2018
$2.3 Million in New Funding Focused on Novel Biomarkers and Treatments
The Alzheimer's Drug Discovery Foundation (ADDF) announces funding for a novel biomarker and two Phase I clinical studies.
-
Initiatives
July 17, 2018
New Coalition of Philanthropists Including Bill Gates, Leonard Lauder to Commit More Than $30 Million to Develop New Tools to Diagnose Alzheimer's Disease
Bill Gates and Leonard Lauder have announced Diagnostics Accelerator, an initiative to develop new biomarkers for early detection for Alzheimer's.
-
New Grants
July 13, 2018
New Investments Fund Research Ranging from Novel Treatments for Postoperative Cognitive Dysfunction to Frontotemporal Degeneration
The Alzheimer's Drug Discovery Foundation (ADDF) announces seven new investments, including clinical trials, novel drug programs, and a prevention program, which reflects the comprehensive nature of the ADDF's funding strategy.
-
New Grants
May 10, 2018
$2.5 Million in New Funding Exemplifies ADDF’s Strategy
We announce $2.5 million in new funding, which reflects the comprehensive nature of our strategy to prevent and treat Alzheimer’s disease.
-
Events
May 7, 2018
Fabrizio Freda and The Estée Lauder Companies Honored at Connoisseur’s Dinner
Fabrizio Freda, President and CEO of The Estée Lauder Companies, was honored at our Annual Connoisseur’s Dinner in New York City. The event raised $2.6 million for Alzheimer’s research.
-
Initiatives
May 1, 2018
Partnership with FNIH Will Drive New Biomarkers for Alzheimer’s
The ADDF has joined an initiative from the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium that will improve diagnosis and the development of targeted therapies for Alzheimer's disease.
-
Events
April 24, 2018
Longtime Partner Neiman Marcus Honored at Great Ladies Luncheon, Hosted by Wolf Blitzer
On Wednesday, April 18, the ADDF raised over $650,000 for innovative research at our Eighth Annual Great Ladies Luncheon & Fashion Show.
-
Events
April 12, 2018
Inaugural Memories Matter Benefit Raises $1.2 Million for Alzheimer’s Drug Research
Our inaugural Memories Matter benefit raised $1.2 million for Alzheimer's drug research.
-
Initiatives
March 28, 2018
ADDF and Harrington Discovery Institute Invite Applications for 2018 ADDF-Harrington Scholar Award
Harrington Discovery Institute and the Alzheimer’s Drug Discovery Foundation (ADDF) announce a request for proposals for the 2018 ADDF-Harrington Scholar Award.
-
Events
March 16, 2018
Kim Campbell Honored at Premiere Women’s Luncheon in Palm Beach, Hosted by Jane Seymour
On Tuesday, March 13, the Alzheimer’s Drug Discovery Foundation (ADDF) honored Kim Campbell for her charitable work at our Premiere Women’s Luncheon at Club Colette in Palm Beach.
-
New Grants
March 13, 2018
Funding Supports New Approaches to Treat Multiple Types of Dementia
The ADDF announces two investments in programs targeting mitochondria and the progranulin gene.
-
Events
February 20, 2018
ADDF Named an Official Charity Partner of the 2018 New York City Marathon
The Alzheimer’s Drug Discovery Foundation is once again an Official Charity Partner of the 2018 TCS New York City Marathon, which takes place on Sunday, November 4, 2018.
-
New Grants
January 8, 2018
$1.8 Million in New Funding Supports Clinical Stage Treatments
The ADDF announces nearly $1.8 million in new funding, which reflects our commitment to advancing drugs in or near human clinical trials.
-
New Grants
November 14, 2017
Three New Grants Keep Promising Programs Forging Ahead
The Alzheimer’s Drug Discovery Foundation (ADDF) announces three new investments, all of which are for programs that the ADDF previously funded.
-
Research Update
November 1, 2017
New Report Highlights Innovation in Alzheimer’s Clinical Trials
Closing in on a Cure: 2017 Alzheimer’s Clinical Trials Report surveys the 126 drugs in clinical development for Alzheimer’s disease—20% of which received support from the Alzheimer’s Drug Discovery Foundation.
-
Events
October 30, 2017
Sharon Sager of UBS Honored for Support of Alzheimer’s Research
Sharon Sager from UBS received The Charles Evans Award at our Eighth Annual Fall Symposium & Luncheon. The event raised over $1.2 million.
-
New Grants
October 24, 2017
Innovative Alzheimer’s Combination Therapy Trial Supported by New Joint Funding Initiative
We are jointly funding a new combination therapy clinical trial for Alzheimer’s disease to be conducted by Amylyx Pharmaceuticals.
-
Initiatives
October 3, 2017
New Project Co-Funded with Pfizer’s Centers for Therapeutic Innovation
The Alzheimer's Drug Discovery Foundation (ADDF) and Pfizer's Centers for Therapeutic Innovation (CTI) announced joint support for a project that could result in a therapeutic for neurodegenerative diseases.
-
Initiatives
September 14, 2017
Dr. Roberta Diaz Brinton Wins Alzheimer’s Drug Discovery Foundation’s Melvin R. Goodes Prize
Dr. Brinton has pioneered a promising neurogenesis therapy for Alzheimer’s disease.
-
Research Update
September 13, 2017
18th Annual Conference on Alzheimer’s Drug Discovery Showcases Non-Amyloid Research
Nearly 200 academic and industry researchers came together to share updates on innovative preclinical and clinical-stage Alzheimer’s disease research at the 18th Annual Conference on Alzheimer's Drug Discovery.
-
New Grants
September 5, 2017
New Funding Supports Blood Test for Early Alzheimer’s
The ADDF announces two new grants, including support for a blood test designed to detect Alzheimer’s disease in early stages of development and a gene therapy for frontotemporal dementia.
-
New Grants
July 11, 2017
Latest Funding Includes Support for Innovative Clinical Trial
The ADDF announces four new grants, including support for an innovative clinical trial, two novel drug programs, and a biomarker for CTE.
-
Research Update
June 29, 2017
2016 Annual Report Released
The 2016 Annual Report, titled “From Idea to Impact,” highlights the enormous progress the ADDF has made toward finding effective treatments for Alzheimer’s disease.
-
Initiatives
June 7, 2017
ADDF and Science Exchange Launch ADDF ACCESS to Advance Research
New “CRO Finder” Connects Scientists with Specialized Resources
-
New Grants
May 15, 2017
$2.6 Million in New Grants Spurs Innovation
We announce 10 new grants totaling over $2.6 million to drive promising new approaches to treating and diagnosing Alzheimer’s and related dementias.
-
Events
May 11, 2017
Tad Smith & Sotheby’s Honored at Connoisseur’s Dinner
11th annual gala raises $2.5 million for lifesaving Alzheimer's treatments
-
Events
April 27, 2017
Author Sally Quinn Honored at Our Great Ladies Luncheon, Hosted by Judy Woodruff
We raised over $350,000 for life-saving research at our Seventh Annual Great Ladies Luncheon & Fashion Show in Washington, DC, which honored author Sally for her work in the fight against Alzheimer's.
-
New Grants
April 24, 2017
ADDF Invests $300,000 to Support Phase 2 Clinical Trial of Epigenetic Therapy
A new investment of $300,000 in Oryzon Genomics continues our support of its groundbreaking epigenetic drug ORY-2001.
-
Research Update
April 20, 2017
ADDF-Funded Scientists Discover Two Repurposed Drugs With Promise for Alzheimer’s and FTD
A team of scientists from the Medical Research Council (MRC) in the UK have found two drugs, which block brain cell death and prevent neurodegeneration in preclinical studies. Their findings were published today in Brain.
-
New Grants
April 13, 2017
ADDF Funding Advances M3 Biotechnology Toward Clinical Trials
Our new investment in M3 Biotechnology is advancing its drug program toward clinical trials
-
New Grants
March 7, 2017
$4 Million in New Grants Support Several First-in-Class Dementia Treatments
We recently awarded eight new grants totaling over $4 million to advance treatments for Alzheimer’s and related dementias. Several of the awards support new approaches to treating these diseases.
-
Events
February 3, 2017
ADDF An Official Charity Partner of the 2017 TCS New York City Marathon
We have been chosen as Official Charity Partner of the TCS New York City Marathon for the third year. The race will take place on Sunday, November 5, 2017.
-
Initiatives
January 18, 2017
Expanded Partnership Increases Support for Drug Discovery
ADDF and Harrington Institute increase funding and resources for promising Alzheimer’s drug discovery programs.
-
Board & Staff
January 10, 2017
Mark Roithmayr Appointed As Our First CEO
Our Board of Governors has appointed Mark Roithmayr as Chief Executive Officer. Mr. Roithmayr is the first person to hold the CEO position at the ADDF.
-
New Grants
January 9, 2017
$2.5 Million in New Grants Advance Clinical Trials of Alzheimer’s Treatments
We awarded three new grants in November and December, totaling nearly $2.5 million. The grants represent our commitment to advancing the most promising drugs to clinical trials, the final stages of drug development.
-
Events
November 15, 2016
Donald Newhouse Honored for His Efforts to End a Rare Form of Dementia
On November 14, Donald Newhouse received The Charles Evans Award from the ADDF at our Seventh Annual Fall Symposium & Luncheon at The Pierre in New York City. Thanks to the generosity of our donors, the Symposium & Luncheon raised nearly $1 million for drug discovery research.
-
New Grants
November 8, 2016
$1.5 Million in New Grant Funding for Promising Treatments
The Alzheimer’s Drug Discovery Foundation awarded three new grants in September and October totaling nearly $1.5 million.
-
Initiatives
October 27, 2016
Alzheimer’s Drug Discovery Foundation Launches Expanded Brain Health and Dementia Prevention Website
The streamlined site separates fact from fiction and empowers people to make smarter choices for their brain health.
-
New Grants
September 29, 2016
New Clinical Trial Will Test Cancer Drug as Alzheimer’s Treatment
Dr. Howard Fillit, the ADDF's Founding Executive Director and Chief Science Officer, says: "The ADDF is proud to support a clinical trial that holds such promise for Alzheimer's patients. This funding is part of our wider initiative to use the knowledge gained from cancer research to advance effective treatments for Alzheimer's."
-
Research Update
September 27, 2016
Experimental Imaging Agent Reveals Concussion-Linked Brain Disease in Living Brain
Protein tracer shows distinctive pattern of brain protein deposition specific to this disease and typically confirmed after death
-
New Grants
September 22, 2016
Vivreon Biosciences Awarded Grant to Advance Drug Program Targeting Neuroinflammation
Vivreon Biosciences, LLC has been awarded a preclinical drug discovery grant from the Alzheimer's Drug Discovery Foundation (ADDF) to develop compounds that targets brain inflammation in Alzheimer's disease.
-
New Grants
September 21, 2016
$1.7 Million Grant Supports Promising Drug That Targets Cannabinoid Receptor
With a $1.7 million award from the ADDF, a new biotech created by Cleveland Clinic Innovations is developing a novel drug that reduces inflammation in the brain by targeting a cannabinoid receptor.
-
Research Update
September 13, 2016
Dr. D. Martin Watterson Wins Second Melvin R. Goodes Prize
Dr. Watterson has identified a number of new classes of Central Nervous System drugs.
-
New Grants
September 12, 2016
Three New Grants Support Promising Treatments for Alzheimer’s Disease
The ADDF awarded three new grants in July and August for potential new treatments for Alzheimer's and other dementias.
-
Research Update
August 24, 2016
Panel of Experts Calls for Comparative Effectiveness Research
With better evidence, routine medical decisions could help prevent dementia.
-
New Grants
July 7, 2016
Five New Grants Fund Promising Treatments & Biomarkers
The ADDF awarded five new grants in May and June 2016, totaling nearly $1.5 million.
-
Initiatives
May 13, 2016
Lauder and Newhouse Families Announce New Initiative to Find Treatments for Frontotemporal Dementia
The Lauder Foundation, Leonard A. Lauder, President, and Ronald S. Lauder have committed $5 million, which will be combined with $5 million from the Samuel I. Newhouse Foundation to create The Treat FTD Fund. The fund, a joint program of AFTD and the ADDF, will accelerate clinical trials for FTD over the next decade.
-
New Grants
May 10, 2016
Ten New Grants Support Alzheimer’s Drug Discovery and Biomarker Development
The ADDF has awarded 10 new grants to researchers developing drugs for neurodegenerative diseases and biomarkers to detect their onset and progression.
-
Events
April 29, 2016
Ronald S. Lauder Honored at Connoisseur’s Dinner
Annual Gala Raised over $3.25 million for Alzheimer’s Treatments
-
Events
April 14, 2016
Trish and George Vradenburg Honored at Great Ladies Luncheon, Hosted by Chris Wallace
Sixth Annual Great Ladies Luncheon & Fashion Show most successful in event's history
-
Events
March 9, 2016
ADDF Again Named an Official Charity Partner of the 2016 TCS New York City Marathon
For the second year in a row, the ADDF has been chosen as an Official Charity Partner of the 2016 TCS New York City Marathon. The race will take place on Sunday, November 6, 2016.
-
New Grants
February 25, 2016
Five New Grants Support Drug Discovery and Prevention
Grants awarded in the first two months of 2016 support researchers in the U.S. and Middle East pursuing drug programs, prevention studies, and research to accelerate clinical trials.
-
Initiatives
February 2, 2016
ADDF Joins BIRAX Regenerative Medicine Initiative
The Alzheimer's Drug Discovery Foundation (ADDF) has joined the BIRAX Initiative, which recently issues its third call for proposals. BIRAX brings together British and Israeli scientists to tackle some of the world’s most challenging diseases including cardiovascular and liver disease, diabetes and Parkinson’s.
-
Initiatives
January 12, 2016
PsychoGenics and the ADDF Announce a Risk-Sharing Partnership for Preclinical Studies
We are partnering with PsychoGenics Inc. to bring its services to our grantees working on preclinical Alzheimer’s drug discovery programs.
-
New Grants
January 5, 2016
Five New Research Grants Support Clinical and Early-Stage Programs
Funded Researchers are pursuing diverse targets to treat Alzheimer's disease.
-
Board & Staff
December 29, 2015
New Members Deepen Research & Investment Expertise of ADDF Boards
At the December joint meeting, the ADDF Boards of Governors and Overseers welcomed seven new members.
-
Events
November 10, 2015
Margaret and Daniel Loeb Honored at Our Sixth Annual Fall Symposium & Luncheon
On November 9, Margaret and Daniel Loeb received The Charles Evans Award at our Annual Fall Symposium & Luncheon, which raised more than $1 million.
-
New Grants
November 4, 2015
New Grant Supports AlzeCure’s Work on Neurorestorative Drug
AlzeCure Foundation announced today that it has been awarded a grant from the ADDF to support the further development of its small molecule neurorestorative project.
-
Research Update
September 16, 2015
Dr. Frank Longo Wins Inaugural Melvin R. Goodes Prize
Dr. Longo's pioneering approach may soon lead to new disease modifying drugs.
-
New Grants
August 26, 2015
ADDF and Harrington Discovery Institute Announce 2015 Award Recipients
Collaboration advances development of therapeutics for the treatment of Alzheimer’s Disease.
-
Initiatives
August 24, 2015
ADDF to be Featured in Upcoming Episode of Innovations with Ed Begley Jr.
The ADDF is featured in an episode of Innovations with Ed Begley Jr. on the Discovery Channel.
-
Initiatives
August 12, 2015
Goodes Family & The ADDF Create New Prize for Alzheimer’s Drug Development Researchers
Melvin R. Goodes Prize supports innovative projects by top researchers while honoring the legacy of the former Warner-Lambert CEO.
-
Initiatives
August 6, 2015
Carmel Valley, California Winery Launches Two New Wines to Benefit the ADDF
Jarman Wines, a winery in Carmel Valley, will introduce two premium varietals to benefit the ADDF and to honor the matriarch of the family whose name graces the wines created for her.
-
Research Update
July 30, 2015
Grantees at Lou Rovo Center for Brain Health Recruiting for New Alzheimer’s Disease Trial
Cleveland Clinic Lou Ruvo Center for Brain Health is recruiting participants for a trial to determine if treatment with rasagiline improves brain glucose metabolism and memory.
-
Events
May 4, 2015
Alzheimer’s Drug Discovery Foundation Connoisseur’s Dinner Raises $2.8 Million
On April 27, 2015, Susan Stroman hosted the ADDF's Ninth Annual Connoisseur’s Dinner, which raised more than $2.8 million for Alzheimer's drug discovery and development.
-
Events
April 17, 2015
Diane Rehm Hosts 2015 Great Ladies Luncheon & Fashion Show
Renowned journalist and NPR host Diane Rehm spoke about the need to increase support for drug discovery for Alzheimer's at the ADDF's Annual Great Ladies Luncheon & Fashion Show.
-
New Grants
April 9, 2015
Asceneuron Awarded Alzheimer’s Drug Discovery Foundation Grant
Asceneuron SA, an emerging leader in small molecule therapeutics targeting tauopathies for Alzheimer's and related neurodegenerative diseases, was awarded a $325,000 grant from the ADDF to support the development of its tau modulators.
-
New Grants
March 17, 2015
GliaCure Receives $1 Million Grant for Alzheimer’s Clinical Trial
The ADDF awarded $1 million to GliaCure to co-fund a Phase 1b clinical trial in patients with mild to moderate Alzheimer's disease.
-
Events
March 3, 2015
Alzheimer’s Drug Discovery Foundation an Official Charity Partner of 2015 TCS New York City Marathon
The ADDF is pleased to announce that it is an Official Charity Partner of the 2015 TCS New York City Marathon.
-
Initiatives
February 11, 2015
ADDF Teams Up with Pfizer CTI to Support Discovery of Drugs for Alzheimer’s Disease
The ADDF and Pfizer’s Centers for Therapeutic Innovation are collaborating to advance the development of new small-molecule drugs for Alzheimer’s disease and related dementias.
-
New Grants
January 28, 2015
New Approach to Delay Alzheimer’s Dementia Onset to Be Tested in Phase-3 Clinical Trial
The ADDF announced today a grant to AgeneBio in support of an FDA-registered Phase 3 clinical trial of AGB101, a new therapeutic treatment for amnestic mild cognitive impairment.
-
New Grants
December 18, 2014
New Funding for Italian Biotechnology Company Exploring Novel Drugs for Alzheimer’s Disease
The ADDF has awarded a follow-on grant to Axxam to further develop small molecule drugs to treat Alzheimer's disease by targeting inflammation.
-
New Grants
December 11, 2014
Erectile Dysfunction Drug to Be Tested as Dementia Treatment
The ADDF and the Alzheimer's Society UK announced new funding to explore the possibility of using tadalafil, a commonly prescribed drug which treats erectile dysfunction, as the next treatment for dementia.
-
Events
November 4, 2014
Alzheimer’s Drug Discovery Foundation Honors B. Smith at Fifth Annual Fall Symposium & Luncheon
Former model and restaurateur B. Smith was honored by the ADDF at its Fifth Annual Fall Symposium & Luncheon for raising public awareness and critical funds to combat Alzheimer's disease.
-
Initiatives
September 10, 2014
New Platform Powered by OnDeckBiotech Connects Researchers with Drug Discovery Expertise
The ADDF and OnDeckBiotech announced the relaunch of ADDF ACCESS as a new and improved platform to connect scientists with a virtual network of contract research organizations.
-
Initiatives
June 26, 2014
Leading Foundations Publish Recommendations to Accelerate Drug Repurposing
A peer-reviewed publication from the ADDF and The Michael J. Fox Foundation for Parkinson’s Research offers strategic insight on how organizations can advance the repurposing of FDA-approved drugs for treating neurodegenerative diseases.
-
Initiatives
June 26, 2014
Alzheimer’s Drug Discovery Foundation and OnDeckBiotech Partner to Expand ADDF ACCESS Network
The ADDF and OnDeckBiotech announced a strategic partnership to provide a new platform technology for ADDF ACCESS. Utilizing OnDeckBiotech's technology, ADDF ACCESS will increase the efficiency of contracting drug development services.
-
New Grants
June 9, 2014
ADDF and Harrington Discovery Institute Announce 2014 Award Recipients
Researchers from The Ohio State and Emory Universities will be the first recipients of drug discovery funding and innovation support from a new partnership between the ADDF and Harrington Discovery Institute.
-
Research Update
May 2, 2014
Alzheimer’s Drug Discovery Foundation Raises $1.1M for New Clinical Trial in Alzheimer’s
The ADDF raised more than $1.1 million at its Eighth Annual Connoisseur's Dinner to go to Jeffrey Cummings, MD in support of a clinical trial for a repurposed drug for treating Alzheimer's disease.
-
Initiatives
April 23, 2014
ADDF Launches New Cognitive Vitality Site to Meet Critical Need in Alzheimer’s Prevention
The ADDF launched Cognitive Vitality, an online resource that provides overviews and analyses of dementia prevention strategies.
-
Initiatives
March 24, 2014
Leading Foundations Partner to Accelerate Critical Biomarker Research in AD and Related Dementias
In partnership with the ADDF, the Alzheimer's Disease and Dementia Initiative at the New York Academy of Sciences has awarded a grant to Blaine Roberts, PhD, at The Florey Institute of Neuroscience and Mental Health.
-
Initiatives
March 14, 2014
New Partnership to Provide Drug Discovery Resources for Neurofibromatosis Research Community
The ADDF and the Children's Tumor Foundation announced a partnership to provide CTF's community of neurofibromatosis researchers access to the ADDF ACCESS program.
-
New Grants
March 11, 2014
ADDF and AFTD Award Grants Funding Research on Investigational Therapies to Treat Dementia
The ADDF and The Association for Frontotemporal Degeneration announced the recipients of their seventh annual partnership awards program to accelerate drug discovery for frontotemporal degeneration.
-
New Grants
February 27, 2014
ADDF and FMM Partner to Support Novel Research for Mitochondrial-Directed Therapies
The ADDF and the Foundation for Mitochondrial Medicine awarded $200,000 to James Bennett, M.D., Ph.D. to further research gene therapy of mitochondrial protein in mice with experimental Alzheimer's disease.
-
Initiatives
January 28, 2014
ADDF and W. Garfield Weston Foundation Collaborate to Fund Clinical Trial in Alzheimer’s
The ADDF and The W. Garfield Weston Foundation announced a funding collaboration to support a clinical trial investigating the potential for hypertension drugs to slow Alzheimer's disease progression.
-
Initiatives
January 24, 2014
Foundations Partner on $3M Initiative to Accelerate Research + Discover Treatments for Alzheimer’s
The ADDF and the Alzheimer’s Society (UK) announced a new partnership that intends to fund projects up to $1.5 million each focused on drug repurposing.
-
Initiatives
November 6, 2013
ADDF Expands its ADDF ACCESS Program to Improve Quality and Efficiency of Drug Research
The ADDF expanded its ACCESS program to provide a virtual network of drug discovery experts and contract research organizations that can expedite the development of therapies for neurodegenerative diseases.
-
Events
October 24, 2013
The ING New York City Marathon: Who Runs? Chris Johnson.
Chris Johnson, son of legendary New York Giants Running Back Ron Johnson, has taken up the cause to find a cure for Alzheimer's disease.
-
Initiatives
October 24, 2013
ADDF Partners with Harrington Discovery Institute at University Hospitals Case Medical Center
The ADDF and the Harrington Discovery Institute's partnership leverages their combined expertise and resources to advance promising Alzheimer's drug discovery projects.
-
Initiatives
August 26, 2013
The Horizon Tank: A Gomez-Gracia Limited Edition, Designed for the ADDF
London-based luxury designer Patricia Gomez-Garcia created this limited edition item in support of the ADDF.
-
Events
August 20, 2013
ADDF Presents its September 2013 14th International Conference on Alzheimer’s Drug Discovery
The ADDF presents its annual fall conference on Alzheimer's drug discovery on September 9-10, 2013 in Jersey City, New Jersey.
-
Initiatives
July 1, 2013
The Alzheimer’s Drug Discovery Foundation Launches ADDF Access
The ADDF launched the ADDF ACCESS program to give academic and small biotechnology communities online access to industry standard preclinical drug discovery and development services.
-
New Grants
June 12, 2013
ADDF Supports Madera Biosciences to Advance Small Molecule Drugs that Upregulate APOE
The ADDF announced that it has awarded follow-on funding to Madera Biosciences, Inc. to further develop its small molecule drugs designed to clear accumulated beta-amyloid from the brain.
-
New Grants
April 24, 2013
Research Foundations Collaborate to Fund Ph 1 Study of Cancer Drug In Alzheimer’s Disease Patients
The ADDF and BrightFocus Foundation announced a funding collaboration to support a Phase I clinical trial to evaluate the cancer drug bexarotene as a treatment for Alzheimer's.
-
New Grants
March 25, 2013
Alzheimer’s Drug Discovery Foundation and Lewy Body Dementia Association Award Two Grants to Support
The ADDF and the Lewy Body Dementia Association awarded two grants of $100,000 each to support research on developing biomarkers for dementia with Lewy bodies.
-
New Grants
March 6, 2013
Alzheimer’s Drug Discovery Foundation Awards Grant To Cohbar To Develop A Novel Peptide Therapeutic
The ADDF has awarded $205,260 in funding to CohBar Inc. to develop a mitochondrial peptide, which has been shown to have neuroprotective effects.
-
Research Update
February 28, 2013
Research Foundations Collaborate to Fund Repository of Promising CNS-Active Compounds
The Alzheimer's Drug Discovery Foundation, Beyond Batten Disease Foundation, and the National Multiple Sclerosis Society announced a funding collaboration to support the creation of the Collaborative CNS Screening Initiative.
-
Research Update
February 5, 2013
Medicare Panel’s Failure to Recommend Payment for New Alzheimer’s Diagnostic Brain Imaging Scans
Howard Fillit, MD and George Vradenburg of USAgainstAlzheimer's issued a joint statement, responding to MEDCAC's opinion to not support Medicare reimbursement for PET amyloid imaging scans.
-
Research Update
April 6, 2012
ADDF’s Seed Funding Leads to FDA Approval of Amyvid™, First Diagnostic Test for Alzheimer’s Disease
The FDA has approved Amyvid™, the first diagnostic test for Alzheimer's disease, for which the ADDF provided critical seed funding.
View More